Drugs / MesoPher
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05304208 | Nov 2021 → Dec 2027 expected | malignant pleural mesothelioma | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05650918 | Aug 2021 → May 2023 | malignant pancreatic neoplasm | Joachim Aerts, MD PhD | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03610360 Comparator | Jun 2018 → Jun 2022 | mesothelioma | Amphera BV | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-13 | Alligator Bioscience AB | Results REACtiVe-2 Phase 1 data featuring mitazalimab demonstrate immune activation in metastatic pancreatic cancer – to be presented at ESMO 2025 alligatorbioscience.se ↗
The investigator-sponsored trial, conducted at Erasmus MC Cancer Institute, demonstrated that the combination of mitazalimab and Amphera’s dendritic cell vaccine MesoPher was safe and well-tolerated, with enhanced systemic and local immune responses. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-13 | Alligator Bioscience AB | REACtiVe-2 Phase 1 data featuring mitazalimab demonstrate immune activation in metastatic pancreatic cancer – to be presented at ESMO 2025 alligatorbioscience.se ↗ |
| 2023-04-27 | Alligator Bioscience AB | Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer alligatorbioscience.se ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MesoPher | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610360 ↗ |
| Modality | Cell therapy | “autologous dendritic cells loaded with PheraLys” NCT03610360 ↗ |
| Route | Intravenous | “dendritic cells were administered intravenously” PMID 38848742 ↗ Jun 2024 |